Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a gene-editing strategy to overcome genetic intractability in <i>Lactobacillus johnsonii</i>.

Journal of bacteriology·2026
Same author

Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.

American journal of respiratory and critical care medicine·2026
Same author

<i>Lactobacillus johnsonii</i> and host communication: insight into modulatory mechanisms during health and disease.

Frontiers in microbiomes·2026
Same author

Targeted lung <i>Lactobacillus johnsonii</i> intervention alleviates virus-induced fibrosis post-HCT through PD-L1/PD-1 signaling.

Science advances·2026
Same author

Changes in Microbiome Correspond with Diminished Lung Pathophysiology Following Early-Life Respiratory Syncytial Virus Infection or Antibiotic Treatment: Microbiome Following RSV Infection.

Viruses·2025
Same author

Extracellular iron and the lung microbiome in smoking and COPD.

ERJ open research·2025

Related Experiment Video

Updated: Jul 18, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Cryptococcus neoformans produces authentic prostaglandin E2 without a cyclooxygenase.

John R Erb-Downward1, Gary B Huffnagle

  • 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, USA.

Eukaryotic Cell
|December 13, 2006
PubMed
Summary

Researchers identified prostaglandin E(2) in the fungus Cryptococcus neoformans using mass spectrometry. This discovery suggests novel enzymes are involved in prostaglandin synthesis in eukaryotes.

More Related Videos

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Cellular Lipid Extraction for Targeted Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry Analysis
09:26

Cellular Lipid Extraction for Targeted Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry Analysis

Published on: November 17, 2011

Related Experiment Videos

Last Updated: Jul 18, 2026

Prostaglandin Extraction and Analysis in Caenorhabditis elegans
08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Cellular Lipid Extraction for Targeted Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry Analysis
09:26

Cellular Lipid Extraction for Targeted Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry Analysis

Published on: November 17, 2011

Area of Science:

  • Biochemistry
  • Mycology
  • Molecular Biology

Background:

  • Single-celled eukaryotes are known to produce prostaglandin-like molecules.
  • However, the precise identity and synthesis pathways of these molecules remain largely unverified, particularly in fungi.
  • Mass spectrometry has been lacking for definitive identification.

Purpose of the Study:

  • To definitively identify and characterize prostaglandin E(2) in the pathogenic yeast Cryptococcus neoformans.
  • To investigate the enzymatic pathways responsible for prostaglandin synthesis in this organism.
  • To determine if the canonical cyclooxygenase pathway is involved.

Main Methods:

  • Isolation and identification of prostaglandin E(2) from Cryptococcus neoformans.
  • Utilized liquid chromatography-tandem mass spectrometry (LC-MS/MS) for molecular identification.
  • Tested the effects of cyclooxygenase inhibitors on prostaglandin synthesis.

Main Results:

  • Authentic prostaglandin E(2) was successfully isolated and identified from Cryptococcus neoformans via LC-MS/MS.
  • Prostaglandin synthesis in this organism was not inhibited by cyclooxygenase inhibitors.
  • The genome of Cryptococcus neoformans lacks a cyclooxygenase homolog.

Conclusions:

  • Cryptococcus neoformans synthesizes prostaglandin E(2) through a non-canonical pathway.
  • Novel enzymes, distinct from cyclooxygenase, are responsible for prostaglandin synthesis in this fungus.
  • This finding opens new avenues for understanding lipid mediator production in eukaryotes.